Our clinical trials of tildacerfont in adults with classic CAH, CAHmelia 203 and CAHmelia 204, are open for screening | LEARN MORE


Polycystic Ovary Syndrome (PCOS) is a hormonal disorder that affects approximately five million women in the U.S. and approximately 115 million women worldwide. Tildacerfont may benefit a population of women with a rare form of PCOS caused by hyperresponsiveness to adrenal androgens. There are an estimated 150,000-200,000 women in the U.S. living with this rare form of the disease.

Spruces plans to initiate a Phase 2 proof of concept trial in patients with this form of PCOS in 2021.